155 related articles for article (PubMed ID: 38636144)
21. SCN1A-related phenotypes: Epilepsy and beyond.
Scheffer IE; Nabbout R
Epilepsia; 2019 Dec; 60 Suppl 3():S17-S24. PubMed ID: 31904117
[TBL] [Abstract][Full Text] [Related]
22. KCNT1-related epilepsies and epileptic encephalopathies: phenotypic and mutational spectrum.
Bonardi CM; Heyne HO; Fiannacca M; Fitzgerald MP; Gardella E; Gunning B; Olofsson K; Lesca G; Verbeek N; Stamberger H; Striano P; Zara F; Mancardi MM; Nava C; Syrbe S; Buono S; Baulac S; Coppola A; Weckhuysen S; Schoonjans AS; Ceulemans B; Sarret C; Baumgartner T; Muhle H; Portes VD; Toulouse J; Nougues MC; Rossi M; Demarquay G; Ville D; Hirsch E; Maurey H; Willems M; de Bellescize J; Altuzarra CD; Villeneuve N; Bartolomei F; Picard F; Hornemann F; Koolen DA; Kroes HY; Reale C; Fenger CD; Tan WH; Dibbens L; Bearden DR; Møller RS; Rubboli G
Brain; 2021 Dec; 144(12):3635-3650. PubMed ID: 34114611
[TBL] [Abstract][Full Text] [Related]
23. [Genetically determined epileptic encephalopathies].
Appendino JP; Appendino JI
Medicina (B Aires); 2019; 79 Suppl 3():42-47. PubMed ID: 31603843
[TBL] [Abstract][Full Text] [Related]
24. Not all
Sadleir LG; Mountier EI; Gill D; Davis S; Joshi C; DeVile C; Kurian MA; ; Mandelstam S; Wirrell E; Nickels KC; Murali HR; Carvill G; Myers CT; Mefford HC; Scheffer IE
Neurology; 2017 Sep; 89(10):1035-1042. PubMed ID: 28794249
[TBL] [Abstract][Full Text] [Related]
25. [Clinical features and SCN1A gene mutation analysis of severe myoclonic epilepsy of infancy].
Zhang YH; Sun HH; Liu XY; Ma XW; Yang ZX; Xiong H; Qin J; Lin Q; Wu XR
Zhonghua Er Ke Za Zhi; 2008 Oct; 46(10):769-73. PubMed ID: 19099883
[TBL] [Abstract][Full Text] [Related]
26. SCN1A mutation screening in adult patients with Lennox-Gastaut syndrome features.
Selmer KK; Lund C; Brandal K; Undlien DE; Brodtkorb E
Epilepsy Behav; 2009 Nov; 16(3):555-7. PubMed ID: 19782004
[TBL] [Abstract][Full Text] [Related]
27. The molecular and phenotypic spectrum of IQSEC2-related epilepsy.
Zerem A; Haginoya K; Lev D; Blumkin L; Kivity S; Linder I; Shoubridge C; Palmer EE; Field M; Boyle J; Chitayat D; Gaillard WD; Kossoff EH; Willems M; Geneviève D; Tran-Mau-Them F; Epstein O; Heyman E; Dugan S; Masurel-Paulet A; Piton A; Kleefstra T; Pfundt R; Sato R; Tzschach A; Matsumoto N; Saitsu H; Leshinsky-Silver E; Lerman-Sagie T
Epilepsia; 2016 Nov; 57(11):1858-1869. PubMed ID: 27665735
[TBL] [Abstract][Full Text] [Related]
28. Clinical and genetic study of developmental and epileptic encephalopathy in Argentinean pediatric patients.
Juanes M; Loos M; Reyes G; Veneruzzo G; García FM; Aschettino G; Calligaris S; Martín ME; Foncuberta ME; Alonso CN; Caraballo RH
Medicina (B Aires); 2022; 82(6):856-865. PubMed ID: 36571524
[TBL] [Abstract][Full Text] [Related]
29. Epilepsy phenotype associated with a chromosome 2q24.3 deletion involving SCN1A: Migrating partial seizures of infancy or atypical Dravet syndrome?
Lim BC; Hwang H; Kim H; Chae JH; Choi J; Kim KJ; Hwang YS; Yum MS; Ko TS
Epilepsy Res; 2015 Jan; 109():34-9. PubMed ID: 25524840
[TBL] [Abstract][Full Text] [Related]
30. Children With Trisomy 21 and Lennox-Gastaut Syndrome With Predominant Myoclonic Seizures.
Macdonald M; Crawford J; Datta AN
J Child Neurol; 2021 Oct; 36(11):1027-1033. PubMed ID: 34315269
[TBL] [Abstract][Full Text] [Related]
31. Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes.
de Lange IM; Gunning B; Sonsma ACM; van Gemert L; van Kempen M; Verbeek NE; Nicolai J; Knoers NVAM; Koeleman BPC; Brilstra EH
Epilepsia; 2018 Jun; 59(6):1154-1165. PubMed ID: 29750338
[TBL] [Abstract][Full Text] [Related]
32. Treatment of epileptic encephalopathies.
McTague A; Cross JH
CNS Drugs; 2013 Mar; 27(3):175-84. PubMed ID: 23397290
[TBL] [Abstract][Full Text] [Related]
33. The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications.
Brunklaus A; Brünger T; Feng T; Fons C; Lehikoinen A; Panagiotakaki E; Vintan MA; Symonds J; Andrew J; Arzimanoglou A; Delima S; Gallois J; Hanrahan D; Lesca G; MacLeod S; Marjanovic D; McTague A; Nuñez-Enamorado N; Perez-Palma E; Scott Perry M; Pysden K; Russ-Hall SJ; Scheffer IE; Sully K; Syrbe S; Vaher U; Velayutham M; Vogt J; Weiss S; Wirrell E; Zuberi SM; Lal D; Møller RS; Mantegazza M; Cestèle S
Brain; 2022 Nov; 145(11):3816-3831. PubMed ID: 35696452
[TBL] [Abstract][Full Text] [Related]
34. Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice.
Alonso-Singer P; Aguilar-Amat Prior MJ; Oliva-Navarro J; Massot-Tarrús A; Giráldez BG; Bermejo P; DeToledo-Heras M; Aledo-Serrano Á; Martínez-Cayuelas E; Tirado-Requero P; Velázquez-Fragua R; López-Sobrino G; Ojeda J
Epilepsy Behav; 2022 Sep; 134():108836. PubMed ID: 35870432
[TBL] [Abstract][Full Text] [Related]
35. De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome.
Suls A; Jaehn JA; Kecskés A; Weber Y; Weckhuysen S; Craiu DC; Siekierska A; Djémié T; Afrikanova T; Gormley P; von Spiczak S; Kluger G; Iliescu CM; Talvik T; Talvik I; Meral C; Caglayan HS; Giraldez BG; Serratosa J; Lemke JR; Hoffman-Zacharska D; Szczepanik E; Barisic N; Komarek V; Hjalgrim H; Møller RS; Linnankivi T; Dimova P; Striano P; Zara F; Marini C; Guerrini R; Depienne C; Baulac S; Kuhlenbäumer G; Crawford AD; Lehesjoki AE; de Witte PA; Palotie A; Lerche H; Esguerra CV; De Jonghe P; Helbig I;
Am J Hum Genet; 2013 Nov; 93(5):967-75. PubMed ID: 24207121
[TBL] [Abstract][Full Text] [Related]
36. Novel SCN1A variants in Dravet syndrome and evaluating a wide approach of patient selection.
Surovy M; Soltysova A; Kolnikova M; Sykora P; Ilencikova D; Ficek A; Radvanszky J; Kadasi L
Gen Physiol Biophys; 2016 Jul; 35(3):333-42. PubMed ID: 27045673
[TBL] [Abstract][Full Text] [Related]
37. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions.
Specchio N; Wirrell EC; Scheffer IE; Nabbout R; Riney K; Samia P; Guerreiro M; Gwer S; Zuberi SM; Wilmshurst JM; Yozawitz E; Pressler R; Hirsch E; Wiebe S; Cross HJ; Perucca E; Moshé SL; Tinuper P; Auvin S
Epilepsia; 2022 Jun; 63(6):1398-1442. PubMed ID: 35503717
[TBL] [Abstract][Full Text] [Related]
38. Epilepsy with myoclonic-atonic seizures, also known as Doose syndrome: Modification of the diagnostic criteria.
Oguni H
Eur J Paediatr Neurol; 2022 Jan; 36():37-50. PubMed ID: 34883415
[TBL] [Abstract][Full Text] [Related]
39. SCN1A testing for epilepsy: application in clinical practice.
Hirose S; Scheffer IE; Marini C; De Jonghe P; Andermann E; Goldman AM; Kauffman M; Tan NC; Lowenstein DH; Sisodiya SM; Ottman R; Berkovic SF;
Epilepsia; 2013 May; 54(5):946-52. PubMed ID: 23586701
[TBL] [Abstract][Full Text] [Related]
40. Epileptogenic focal lesions in Dravet syndrome: A warning to investigators.
Ventura R; Beltrán-Corbellini Á; Toledano R; Román IS; García-Morales I; Gil-Nagel A
Epileptic Disord; 2024 Apr; 26(2):173-180. PubMed ID: 38116874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
